EP1804795A4 - Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques - Google Patents

Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques

Info

Publication number
EP1804795A4
EP1804795A4 EP05800096A EP05800096A EP1804795A4 EP 1804795 A4 EP1804795 A4 EP 1804795A4 EP 05800096 A EP05800096 A EP 05800096A EP 05800096 A EP05800096 A EP 05800096A EP 1804795 A4 EP1804795 A4 EP 1804795A4
Authority
EP
European Patent Office
Prior art keywords
cicletanine
disease
agents
alone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05800096A
Other languages
German (de)
English (en)
Other versions
EP1804795A2 (fr
Inventor
Jim Page
Glenn Cornett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CORNETT GLEN
Original Assignee
CORNETT GLEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/035,231 external-priority patent/US20060154971A1/en
Priority claimed from US11/035,308 external-priority patent/US20060153934A1/en
Priority claimed from US11/035,328 external-priority patent/US20060154959A1/en
Priority claimed from US11/232,724 external-priority patent/US20060089374A1/en
Application filed by CORNETT GLEN filed Critical CORNETT GLEN
Publication of EP1804795A2 publication Critical patent/EP1804795A2/fr
Publication of EP1804795A4 publication Critical patent/EP1804795A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP05800096A 2004-09-22 2005-09-22 Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques Ceased EP1804795A4 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US61232304P 2004-09-22 2004-09-22
US61236904P 2004-09-22 2004-09-22
US11/035,231 US20060154971A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and lacidipine
US11/035,308 US20060153934A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and magnesium
US11/035,328 US20060154959A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and carvedilol
US68468405P 2005-05-26 2005-05-26
US11/232,724 US20060089374A1 (en) 2003-07-17 2005-09-21 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
PCT/US2005/034763 WO2006034510A2 (fr) 2004-09-22 2005-09-22 Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques

Publications (2)

Publication Number Publication Date
EP1804795A2 EP1804795A2 (fr) 2007-07-11
EP1804795A4 true EP1804795A4 (fr) 2007-11-07

Family

ID=36090724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05800096A Ceased EP1804795A4 (fr) 2004-09-22 2005-09-22 Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques

Country Status (3)

Country Link
EP (1) EP1804795A4 (fr)
CA (1) CA2581337A1 (fr)
WO (1) WO2006034510A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
ES2525748T3 (es) 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661147A (en) * 1993-09-03 1997-08-26 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
WO2004091612A1 (fr) * 2003-04-15 2004-10-28 SynoSens Kutató és Fejlesztő Kft. Combinaison pharmaceutique synergetique comprenant de la cycletadine pour la prevention ou pour le traitement de diabetes
WO2005009446A1 (fr) * 2003-07-17 2005-02-03 Cotherix, Inc. Polytherapies destinees au traitement de l'hypertension et de complications chez des patients souffrant de diabetes ou du syndrome metabolique
WO2005021039A1 (fr) * 2003-08-29 2005-03-10 Cotherix, Inc. Combinaison de cicletanine et antidiabetique a administration orale et/ou agent de reduction des lipides sanguins en vue du traitement du diabete et du syndrome metabolique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN156817B (fr) * 1981-02-10 1985-11-09 Scras

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661147A (en) * 1993-09-03 1997-08-26 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
WO2004091612A1 (fr) * 2003-04-15 2004-10-28 SynoSens Kutató és Fejlesztő Kft. Combinaison pharmaceutique synergetique comprenant de la cycletadine pour la prevention ou pour le traitement de diabetes
WO2005009446A1 (fr) * 2003-07-17 2005-02-03 Cotherix, Inc. Polytherapies destinees au traitement de l'hypertension et de complications chez des patients souffrant de diabetes ou du syndrome metabolique
WO2005021039A1 (fr) * 2003-08-29 2005-03-10 Cotherix, Inc. Combinaison de cicletanine et antidiabetique a administration orale et/ou agent de reduction des lipides sanguins en vue du traitement du diabete et du syndrome metabolique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUCHHOLZ, R.A. ET AL.: "Natriuretic and diuretic effects of cicletanine in conscious, hydrated, normotensive rats", DRUG DEVELOPMENT RESEARCH, vol. 25, 1992, pages 125 - 137, XP002452886 *
KOHZUKI, M. ET AL.: "Renal-protective effect of nondepressor dose of cicletanine in diabetic rats with hypertension", AMERICAN JOURNAL OF HYPERTENSION, vol. 13, 2000, pages 298 - 306, XP002452885 *
PASSA, P.: "Etude de la tolérance du ciclétanine chez des patients hypertendus présentant des troubles métaboliques", ARCH MAL COEUR, vol. 824, 1989, pages 135 - 138, XP009090138 *

Also Published As

Publication number Publication date
CA2581337A1 (fr) 2006-03-30
WO2006034510A3 (fr) 2006-06-01
EP1804795A2 (fr) 2007-07-11
WO2006034510A2 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
HK1216080A1 (zh) 用於治療或預防草酸鹽相關疾病的組合物和方法
IL177717A0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
IL188420A0 (en) Methods and compositions with enhanced therapeutic activity
IL178894A0 (en) Therapeutic antimicrobial compositions and methods
PT3006040T (pt) Métodos e composições para o tratamento de neuropatias
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL186616A (en) Spyro-oxa-indoles and their use as drugs
EP1737482A4 (fr) Compositions et methodes de traitement de maladies
HK1110508A1 (en) Compositions and methods of their use for improving the condition and appearance of skin
IL191072A0 (en) Therapeutic compositions and methods
GB0523576D0 (en) Drug composition and its use in therapy
EP1758605A4 (fr) Prouroguanyline servant d'agents therapeutiques ou diagnostiques
ZA200701193B (en) The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1933853A4 (fr) Traitement de l'interruption de tissu et composition à employer dans ce traitement
EP1824462A4 (fr) Composition et procede de traitement de tauopathies
EP1757282A4 (fr) Utilisation de composes de kaurane dans l'elaboration d'un medicament
GB2411834B (en) Composition for use in the treatment of dry skin conditions
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP1804795A4 (fr) Compositions enantiomeres de cicletanine, seules ou combinees a d'autres agents, utilisees a des fins therapeutiques
ZA200710476B (en) Methods and compositions for the treatment of pain
EP1812032A4 (fr) Composition a base de facteur tissulaire et methodes associees
GB0505203D0 (en) Skin composition treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070420

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CORNETT, GLENN

Inventor name: PAGE, JIM

A4 Supplementary search report drawn up and despatched

Effective date: 20071010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/00 20060101ALI20071001BHEP

Ipc: A61P 9/12 20060101ALI20071001BHEP

Ipc: A01N 25/00 20060101ALI20071001BHEP

Ipc: A61K 31/4355 20060101AFI20071001BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090929

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20141124